Mage C2 antigenic peptides and uses thereof

Details Mage C2 antigenic peptides and uses thereof Mage C2 antigenic peptides and uses thereof

2008-03-25

2008-03-25

Helms, Larry R. (Department: 1642)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S185100, C424S573000, C530S300000, C530S350000

Reexamination Certificate

active

07348007

ABSTRACT:
This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, β2microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.

REFERENCES:
patent: WO 94/020127 (1994-09-01), None
Tian, J et al, 2004 (Physiol Genomics, 17: 170-182).
Kunkel, P, et al, 2001 (Neuro-oncology 3(2): 82-88).
Drexler et al, 1993 (Leukemia and Lymphoma, 9:1-25).
Embleton et al, 1984 (Immunol Ser, 23:181-207).
Hsu, 1973 (in Tissue Culture Methods and Applications, Kruse and Patterson, Eds, Academic Press, NY, see abstract, p. 764-767.
Chen et al, 1998, PNAS, USA, 95(12): 6919-6923.
Greenbaum et al. (Genome Biology, 2003, vol. 4, Issue 9, pp. 117.1-117.8).
Fu et al 1996 (EMBO Journal, vol. 15, pp. 4392-4401).
Yokota, J et al, 1988 (Oncogene, vol. 3, pp. 471-475).
Hell et al, 1995 (Laboratory Investigation, vol. 73, pp. 492-496).
Banki et al, 1994, JBC, 269 (4): 2847-51.
Bost et al, 1988, Immunol Investigation, 17 (6&7): 577-586).
Kirkin et al, 1998, APMIS, 106 : 665-679.
Gaiger, A et al, 2000 (Blood, 96(4): 1480-1489).
Smith RT, 1994, Clin Immunol, 41(4): 841-849.
Boon (Adv Can Res, 1992, 58:177-210).
Lucas et al, 2000, Intl J Cancer, 87: 55-60.
Gure et al, 2000, Intl J Cancer, 85: 726-732.

Affiliated with

Also associated with

Rating

Mage C2 antigenic peptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mage C2 antigenic peptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mage C2 antigenic peptides and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2806553